Medicure Inc.

MPH on TSXVToday's ChangeVolume52 Week Range (Low/Hi)Market Cap
0.81CAN 1.25%12,7580.7000 - 5.00008.466M

Contact Information

Medicure Inc.

Headquarters:
1250 Waverly Street, Suite 2
Winnipeg, Manitoba
Canada, R3T 6C6
Tel: (204) 488-9823
Email: Send a message
Website: Visit website
For more information...
Lead: Daniel Gordon

Medicure Inc., a pharmaceutical company, engages in the research, development, and commercialization of therapies for the cardiovascular market in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia; and ReDS, a non-invasive medical device that provides measurement of lung fluid for the management of congestive heart failure, as well as Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. The company was founded in 1997 and is headquartered in Winnipeg, Canada

Albert D. Friesen, PhD. - Chief Executive Office & Chairman of the Board
Neil Owens, PhD. - President & Chief Operating Office
James Kinley, CPA, CA - Chief Financial Officer
Reuben Saba, PhD. - Vice President, Scientific and Medical Affairs
 

Albert D. Friesen - Chair
Arnold Naimark, M.D. - Director
Peter Quick - Director
Brent Fawkes, CA - Director 
Gerald P. McDole, MBA - Director
Manon Harvey, CPA, CA, ICD.D - Director

Stock Information

Company Overview

Medicure Inc., a pharmaceutical company, engages in the research, development, and commercialization of therapies for the cardiovascular market in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia; and ReDS, a non-invasive medical device that provides measurement of lung fluid for the management of congestive heart failure, as well as Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. The company was founded in 1997 and is headquartered in Winnipeg, Canada

Management

Albert D. Friesen, PhD. - Chief Executive Office & Chairman of the Board
Neil Owens, PhD. - President & Chief Operating Office
James Kinley, CPA, CA - Chief Financial Officer
Reuben Saba, PhD. - Vice President, Scientific and Medical Affairs
 

Board of Directors

Albert D. Friesen - Chair
Arnold Naimark, M.D. - Director
Peter Quick - Director
Brent Fawkes, CA - Director 
Gerald P. McDole, MBA - Director
Manon Harvey, CPA, CA, ICD.D - Director

Contact Information

Headquarters:
1250 Waverly Street, Suite 2
Winnipeg, Manitoba
R3T 6C6, Canada
Telephone: (204) 488-9823
Email: Send a message
Website: Visit website